Saliva tests, easier to collect than blood samples, show promise in detecting diseases like cavities, infections, and cancer. Despite their potential, these tests face obstacles such as high costs and lack of insurance coverage. Currently, only HIV and COVID-19 saliva tests have FDA approval. However, new Medicare incentives for FDA-approved tests could drive companies to seek approval, potentially expanding coverage. Researchers are working to identify reliable salivary markers, which could lower barriers to healthcare access. Saliva tests could complement traditional dental visits by serving as a health alert system.
